Folate receptors (FRa, FRb and FRc) are cysteine-rich cell-surface glycoproteins that bind folate with high affinity to mediate cellular uptake of folate. Although expressed at very low levels in most tissues, folate receptors, especially FRa, are expressed at high levels in numerous cancers to meet the folate demand of rapidly dividing cells under low folate conditions [1] [2] [3] . The folate dependency of many tumours has been therapeutically and diagnostically exploited by administration of anti-FRa antibodies, high-affinity antifolates 4, 5 , folate-based imaging agents and folate-conjugated drugs and toxins [6] [7] [8] . To understand how folate binds its receptors, we determined the crystal structure of human FRa in complex with folic acid at 2.8 Å resolution. FRa has a globular structure stabilized by eight disulphide bonds and contains a deep open folate-binding pocket comprised of residues that are conserved in all receptor subtypes. The folate pteroate moiety is buried inside the receptor, whereas its glutamate moiety is solvent-exposed and sticks out of the pocket entrance, allowing it to be conjugated to drugs without adversely affecting FRa binding. The extensive interactions between the receptor and ligand readily explain the high folate-binding affinity of folate receptors and provide a template for designing more specific drugs targeting the folate receptor system.
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Folates (vitamin B 9 ) are important one-carbon donors for the synthesis of purines and thymidine-essential components of nucleic acids-and indirectly, via S-adenosyl methionine, for methylation of DNA, proteins and lipids 9 . Folate deficiency is therefore associated with many diseases, including fetal neural tube defects, cardiovascular disease and cancers 10 . In adult tissues, folate is mainly taken up by reduced folate carrier, a ubiquitously expressed anion channel that has relatively low folate-binding affinity (K m 5 1-10 mM)
11
. By contrast, high-affinity uptake of the food supplement folic acid (K d , 1 nM) 12 and the physiologically prevalent folate N 5 -methyltetrahydrofolate (5-mTHF) requires the function of three subtypes of folate receptor (FRa, FRb and FRc), which are cysteine-rich glycoproteins that mediate folate uptake through endocytosis. Inside of the cell, the acidic environment of the endosome promotes the release of folate from receptors, which is then transported into the cytoplasm by proton-coupled folate transporter 13 . The expression of folate receptors is largely restricted to cells important for embryonic development (for example, placenta and neural tubes) and folate resorption (kidney). Among the three FR isoforms, FRa is the most widely expressed, with very low levels in normal tissues, but high expression levels in many tumours 14 . As *These authors contributed equally to this work. -3.000 -3.000 3.000 3.000 such, FRa has become the molecular target for the development of many cancer therapeutics, including anti-FRa antibodies, high-affinity anti-folates, folate-based imaging agents and folate-conjugated drugs and toxins. Despite intense research on the folate structure-activity relationship, the molecular basis for the high-affinity recognition of folates by FRa remains elusive owing to the technical difficulties in expression, purification and crystallization of FRa for structural studies.
To obtain FRa protein for structural studies, we stably expressed human FRa lacking its carboxy-terminal glycophosphatidylinositol anchor as a secreted IgG Fc fusion protein (FRa-Fc) in HEK293 cells. As fully glycosylated fusion protein purified from culture medium yielded poorly diffracting crystals, we reduced crystallization-inhibiting glycosylation heterogeneity by combined treatment with kifunensine and endoglycosidase H, which together reduce complex carbohydrates to single N-acetylglucosamine (NAG) moieties 15 ( Supplementary  Fig. 1a, b) . The deglycosylated FRa-Fc had a similar folic acid-binding affinity (,190 pM) to the fully glycosylated protein ( Supplementary  Fig. 1d ) and yielded crystals, which diffracted to 2.8 Å ( Supplementary  Fig. 1c ). We solved the structure by combining the phase information from one Pt derivative and six native S anomalous data sets (see Methods and Supplementary Table 1 ).
FRa has an overall globular structure, comprising four long a-helices (a1, a2, a3, a6), two short a-helices (a4, a5), four short b-strands (b1-b4) and many loop regions (Fig. 1a, b) . The tertiary structure is greatly stabilized by eight disulphide bonds formed by 16 conserved cysteine residues (C15-C43, C35-C83, C44-C87, C67-C153, C74-C124, C113-C187, C117-C167 and C130-C147). FRa has three predicted N-glycosylation sites at N47, N139 and N179. Clear electron density for NAG is observed for N47 and N139, and partial electron density for N179. The overall fold of FRa is similar to that of riboflavinbinding protein (22% sequence identity to FRa) 16 , with a root mean squared deviation of 1.56 Å for 163 Ca atoms, but the two proteins have very differently shaped ligand pockets and ligand-binding modes (Supplementary Fig. 2 ).
The core domain consists of helices a1, a2, a3 and a5 tied together by four disulphide bridges (C35-C83, C44-C87, C74-C124 and C117-C167; Fig. 1a ). The structure of FRa contains a long and open folatebinding pocket, which is formed by a1, a2 and a3 in the back; the amino-terminal loop, b1 and b2 in the bottom; the a1-a2 and a3-a4 loops in the left and top; and a4, a5, b4 and b3 in the right (Fig. 1a, b) . Folic acid is oriented with its basic pteroate moiety docked deep inside of the negatively charged pocket and the two negatively charged carboxyl groups of its glutamate moiety sticking out of the positively charged 
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entrance of the ligand-binding pocket, which is formed by the a1-a2, b1-b2 and a3-a4 loops (Figs 1 and 2b) .
Clear electron density was observed for folic acid and the surrounding amino acid residues, which allowed for accurate modelling of the ligand and its interacting residues lining the binding pocket ( Fig. 2a and Supplementary Fig. 3) . The cross-section of the binding pocket reveals the complementary shape and charge between the bound ligand and the receptor (Fig. 2b) . Folic acid docks into an extended groove of FRa in the direction roughly perpendicular to the plane formed by helices a1, a2 and a3, with the pterin head group buried inside against the back formed by a1, a2 and a3 (Figs 1a and 2b, c) . The interactions around the pteroate moiety contain both hydrogen bonds and hydrophobic interactions. First, the pterin ring is stacked between the parallel side chains of Y85 and W171, and capped by Y175 (Fig. 2c) . Second, the hydrophilic pterin ring N and O atoms form a series of hydrogen bonds with receptor residues. Specifically, the pterin N1 and N2 atoms form strong hydrogen bonds with the side-chain carboxyl group of D81, the N3 and O4 atoms with the S174 hydroxyl group, the O4 atom forms two hydrogen bonds with the guanidinium groups of R103 and R106, and the N5 atom forms one hydrogen bond with the H135 side chain (Figs 2c and 3a) . Interestingly, folic acid O4 is replaced by an amino group in the antifolates methotrexate and aminopterin, which have reduced affinity for FRa 5, 17 . The amino group would not allow for the formation of hydrogen bonds with R103 and R106 and would sterically clash with the position of R103 (see Fig. 3a ) in the folic acid-bound structure, providing a structural rationale for the poor FRa-binding of these two compounds and their preferential uptake by reduced folate carrier.
The folic acid aminobenzoate is stabilized by hydrophobic interactions with Y60, W102 and W134, which line the middle of the long ligandbinding pocket (Fig. 3a) . Extensive interactions are also observed for the glutamate group, which engages six hydrogen bonds, contributed by the side chains of W102, K136 and W140, as well as by backbone interactions with H135, G137 and W138 (Figs 2c and 3a) . Most residues involved in ligand binding are identical among different subtypes of FR regardless of their origins (Supplementary Figs 4 and 5) , indicating that the observed folate-binding interactions are probably conserved in all three different receptor subtypes. In addition, the most physiologically prevalent folate, 5-mTHF, can be easily docked into the FRa ligand-binding pocket in a mode very similar to that of folic acid, suggesting that the fundamental mechanism of folate recognition is conserved (Supplementary Fig. 6 ).
To validate the structure observations, we examined the ligandbinding affinities of FRa mutants that have alanine mutations in the key folate-contacting residues. The W171A mutation abolished the expression of the receptor (Supplementary Fig. 7a ), suggesting that this residue is critical for protein stability. All other mutants expressed relatively well and were purified to determine their folate-binding affinity by radioligand-binding assay (Supplementary Figs 7b and  8b) . Whereas wild-type FRa bound to [ 3 H]-folic acid with a K d of ,0.19 nM, replacement of D81 decreased affinity by more than one order of magnitude, consistent with the strong interaction of the aspartate carboxyl oxygens with the pterin N1 and N2 nitrogens, and indicating that this interaction is a key contributor to high-affinity ligand binding. By contrast, mutations of Y175, K136 and R106 (bond lengths $ 3.1 Å ) have little effect, and mutations of all other ligandbinding residues (hydrogen bonds # 3.0 Å ) have only moderate effects on folic acid binding (affinity deceases of # 3.6-fold), which are approximately additive for the double mutants R103A/S174A and W102A/ R103A. This extensive interaction network therefore makes FRa-folic acid binding remarkably resistant to single amino acid substitutions (Fig. 3b and Supplementary Figs 7b and 8b) . Together, the structural and mutational analyses present a structural rationale for the absolute requirement of the pterin group for anchoring folate in the binding pocket of the receptor and for the availability of the glutamate group for conjugation with drugs and imaging reagents 18 , without adversely affecting the interactions between receptor and ligand.
In summary, many cancers highly express FRa, which has therefore become an important target for receptor-mediated chemotherapy. How FR binds to folate and folate-conjugated drugs, however, has remained unknown. The FRa-folic acid complex structure illustrates how the receptor assumes a deep folate-binding pocket that is formed by conserved residues across all receptor subtypes and provides detailed insights into how folic acid interacts with its receptors. Together, these observations establish a rational foundation for designing specific drugs targeting the folate receptor system.
METHODS SUMMARY
FRa was stably expressed in HEK293 cells as a secreted IgG Fc fusion protein in cell medium supplemented with folic acid and kifunensine. Proteins were purified from the conditioned cell media by nickel-nitrilotriacetic acid chromatography (Ni-NTA), followed by proteolytic release of the Fc tag, enzymatic deglycosylation and size-exclusion chromatography. Crystals were grown by vapour diffusion. One native data set, one Pt derivative data set and six S anomalous signal data sets were collected from cryo-protected crystals at beamlines 21-ID-D at the Advanced Photon Source at Argonne National Laboratories. 
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Initial phases were established using the SHELX program 19 with Pt-soaked derivative data and S anomalous data. Density modification for the initial electron density map was performed using DM 20 . A crude model was built automatically using the CCP4 program buccaneer, improved by manual building using Coot 21 and using the riboflavin-binding protein structure as a reference. The eight molecules of FR model were located in one asymmetric unit by molecular replacement and further refined using the Refmac program of CCP4 (ref. 22) .
Mutant proteins were expressed in HEK293 cells after transient transfection and purified using Ni-NTA chromatography. Folic acid binding was determined by saturation radioligand-binding assay using
METHODS
Protein expression and purification. The human FRa (residues 23-234) complementary DNA excluding the secretion signal peptide (residues 1-22) and glycophosphatidylinositol anchor signal peptide (residue 235-257) was expressed as a human IgG Fc fusion protein from the expression vector pcDNA6. This construct also contained a murine Igk leader sequence at the N terminus to allow target protein secretion into media supernatant, a thrombin cleavage site between FRa and Fc, and a His 6 tag after the Fc tag. For small-scale expression, HEK293 cells were transiently transfected with the FRa-Fc DNA. Media supernatants were collected after 4 days and dialysed against 20 mM Tris, pH 8.0, 0.15 M NaCl, 5% glycerol before nickel-nitrilotriacetic acid (Ni-NTA) chromatography. For largescale purification, a stable HEK293 cell line expressing FRa-Fc was established by selection of HEK293 cells transiently transfected with FRa-Fc DNA in the presence of 10 mg ml 21 blasticidin (Invitrogen). Single colonies were grown in 24-well plates and expression of secreted FRa-Fc fusion protein in cell media supernatants was examined by biolayer interferometry using an Octet Red instrument (ForteBio) and by immunoblot analysis.
For large-scale purifications, a stable clone was maintained in 500 ml of DMEM supplemented with 5% fetal bovine serum, 20 mM HEPES, 5 mM kifunensine and 200 mM folic acid in one-litre roller bottles at 37 uC. Two litres of conditioned media were collected, concentrated to 400 ml and dialysed against buffer C (25 mM Tris, pH 8.0, 150 mM NaCl, 1 mM folic acid) at 4 uC overnight before loading on a 50-ml Ni-chelating Sepharose column (GE Healthcare). The column was washed with 300 ml buffer A (25 mM Tris, pH 8.0, 150 mM NaCl, 25 mM imidazole, 10% glycerol, 1 mM folic acid) and eluted with buffer A plus 500 mM imidazole. Peak fractions were pooled, digested with thrombin at a 1:1,000 mass ratio during overnight dialysis against buffer C at 4 uC to remove imidazole, and loaded on a 5-ml Ni-chelating Sepharose column (GE Healthcare) to remove the Fc His 6 tag. The flow-through was collected, adjusted to pH 5.6 and deglycosylated with endoglycosidase H f (New England Biolabs). Deglycosylated protein was finally separated by Sephadex S-200 gel filtration in 25 mM Tris, pH 8.0, 200 mM ammonium acetate, 1 mM EDTA and 1 mM folic acid. The protein eluted from the gel-filtration column at a volume corresponding to the size of a monomer at a purity .95% as judged by SDS-PAGE (Supplementary Fig. 1 ). Crystallization. Purified FRa protein was concentrated to about 7 mg ml 21 before crystallization trials. Initial screening identified that polyethylene glycol (PEG) is favourable for crystal formation. Optimization trays using PEG were set up manually using the hanging drop method at 20 uC. Needle-shaped crystals were obtained, which diffracted X-rays to about 9-10 Å . To reduce glycosylation, FRa protein was expressed in the presence of 5 mM kifunensine (GlycoSyn) 15 and purified FRa protein was further deglycosylated with endoglycosidase H f (New England Biolabs) (Supplementary Fig. 1 ). Crystals were grown at 20 uC in hanging drops containing 1.5 ml of the purified protein and 1 ml of well solution (0.1 M MES, pH 6.5, 12% (v/v) PEG 2000, 0.15 M potassium sodium tartrate). Crystals appeared within 5-6 days and grew to a dimension of ,250 mm in length with a hexagonal shape by day 14. These crystals diffracted to 2.8 Å at the Advanced Photon Source (APS) synchrotron, Life Sciences Collaborative Access Team (LS-CAT). Data collection and structure determination. Crystals were transferred to well solution with 20% (v/v) ethylene glycol as a cryoprotectant before flash freezing in liquid nitrogen. Data collection was performed at sector 21-ID-D (LS-CAT) of the APS synchrotron using single native crystals and the diffraction data were processed with HKL2000 (ref. 23 ). On the basis of Matthew's coefficient calculation, the crystals have an unusually large unit cell with an estimate of 8-10 molecules per asymmetric unit. Initial structure determination by molecular replacement using riboflavin-binding protein (which shares 22% sequence identity with FRa) as a search model failed to yield any correct solution. To solve the phase problem, a heavy-atom derivative was prepared by soaking the native FRa crystals with a Pt salt before data collection. Also, six data sets of native FRa were collected at a wavelength of 1.77 Å to measure the S anomalous signal to aid in structure determination. These six data sets were processed using XDS 24 , combined using Pointless, and merged using Scala of the CCP4 suite 25 as previously described 26 . Merging multiple data sets increased the S anomalous signal and redundancy of the data, but also led to an increase of the merging R-factor 26 . Initial phases were established by using the SHELX program 19 with Pt-soaked derivative data and native data (Supplementary Table 1 ). Fifteen Pt atoms were found by SHELXD with a CC/CC weak score of 31.4/17.1 (CC is the correlation coefficient between E calc and E obs for all data and CC weak is the correlation coefficient for 30% of reflections that were not used during the dual-space refinement). Subsequent phasing using SHELXE generated a contrast score of 0.8 and connectivity of 0.79 for the correct hand solution. Density modification for the initial electron density map was performed using DM 20 . A crude model was built automatically using the CCP4 program buccaneer and improved by manual building using Coot 21 . Phases were further improved by using the S anomalous data and a total of 29 S atoms were found based on the anomalous difference Fourier using the Phenix program 27 . The initial FRa model was manually adjusted on the basis of the electron density map using the riboflavin-binding protein structure as a reference and the improved model allowed accurate location of eight molecules in one asymmetric unit by molecular replacement (Supplementary Fig. 9 ). The models were refined against the native data with eight-fold non-crystallographic symmetry restraints using the Refmac program of CCP4 (ref. 22) . The densities for folic acid became clear after several rounds of model adjustments and refinements and eight molecules of folate were built into the model. The final model was refined to an R factor of 0.206 and an R free factor of 0.256 (Supplementary Table 1 ). The Ramachandran statistics are 87% in the favoured regions, 12.5% in additional allowed regions and 0.5% in generously allowed regions. Mutagenesis. Site-directed mutagenesis was carried out using the QuickChange method (Stratagene). Mutations and all plasmid constructs were confirmed by DNA sequencing. Radioligand-binding assay. The binding affinity of each FRa mutant was determined by saturation radioligand-binding assay. 40 nM of each mutant in 100 ml binding buffer (25 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Triton X-100) was immobilized in the wells of a protein G-coated 96-well plate (Thermo Scientific) for 40 min. Endogenous ligand was stripped with 100 ml stripping buffer (25 mM acetate acid, pH 3.5, 150 mM NaCl, 0.1% Triton X-100) for 1 min as described previously 28 . After neutralizing and washing with 200 ml binding buffer, proteins were incubated for 40 min with 100 ml binding buffer supplemented with the indicated concentrations of [
